Longrange Capital closes purchase of US Synthetic

Longrange Capital closes purchase of US Synthetic

Longrange Capital has completed its acquisition of US Synthetic, a prominent healthcare technology company. The transaction, announced on July 2, 2025, involved Longrange Capital issuing 37.5 million common shares in its capital to each shareholder of US Synthetic. The deal was valued at C$0.40 per share of Longrange Capital [3].

US Synthetic, a healthcare technology company headquartered in the San Francisco Bay Area, specializes in synthetic biology and medical device innovation. The acquisition is part of Longrange Capital's strategic expansion into the healthcare sector, aiming to leverage US Synthetic's expertise in synthetic biology and medical devices to drive growth and innovation.

The acquisition follows a period of regulatory uncertainty surrounding cryptocurrency investments, as seen with Basel Medical Group Ltd's halt in its $1 billion Bitcoin acquisition plan. Basel Medical, a Singapore-based orthopedic group, had planned to invest in Bitcoin but deferred the acquisition due to regulatory uncertainties [1]. This pause underscores the broader hesitancy among businesses in digital asset investments, highlighting the need for clearer regulatory guidelines.

Longrange Capital's acquisition of US Synthetic is a significant move in the healthcare technology sector, reflecting the growing interest in digital currencies and blockchain technology among traditional financial institutions. The deal is expected to provide Longrange Capital with a competitive edge in the healthcare technology market, leveraging US Synthetic's innovative capabilities in synthetic biology and medical devices.

As regulatory landscapes continue to evolve, companies like Longrange Capital must navigate these uncertainties carefully to ensure the success of their investments in digital assets. The acquisition of US Synthetic is a strategic move that positions Longrange Capital for growth and innovation in the healthcare technology sector.

References:
[1] https://www.ainvest.com/news/bitcoin-news-today-basel-medical-halts-1-billion-bitcoin-acquisition-due-regulatory-uncertainty-2507/
[2] https://www.crunchbase.com/organization/us-synthetic
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3TD140:0-aaj-capital-3-announces-definitive-agreement-for-qualifying-transaction-with-xrp-healthcare-m-a-holding/